DYAI supply chain intelligence for Dyadic International, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Dyadic International, Inc. (DYAI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CRAIG-HALLUM-CAPITAL-GROUP-LLC | CRAIG-HALLUM-CAPITAL-GROUP-LLC | 92% | The Company may offer and sell from time to time, at its option, shares of the Company’s common stock having an aggregate offering price of up to $4,237,818 from time to time through the Sales Agent. |
| ALPHAZYME-LLC | ALPHAZYME-LLC | 90% | Amended and Restated Non-Exclusive Sublicense Agreement among Dyadic International, Inc., Alphazyme, LLC, dated June 24, 2020 |
| BIOTECHNOLOGY-DEVELOPMENTS-FOR-INDUSTRY-IN-PHARM | BIOTECHNOLOGY-DEVELOPMENTS-FOR-INDUSTRY-IN-PHARM | 90% | Service Framework Agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. dated June 30, 2017 |
| CROS | CROS | 90% | For each of the three months ended March 31, 2026 and 2025, two CROs accounted for $ 651,703 or 63.4 % and $ 483,426 or 77.9 % of total research services we purchased, respectively. |
| DANISCO-US-INC | DANISCO-US-INC | 90% | Pharma License Agreement with Danisco US, Inc. dated December 31, 2015 |
| INZYME | INZYME | 90% | Inzyme Development and Exclusive License Agreement, effective September 18, 2023 |
| LEPRINO-FOODS-COMPANY | LEPRINO-FOODS-COMPANY | 90% | Joint Development Agreement with Leprino Foods Company, dated May 12, 2022 |
| PROLIANT-BIOLOGICALS-LLC-D-B-A-PROLIANT-HEALTH-A | PROLIANT-BIOLOGICALS-LLC-D-B-A-PROLIANT-HEALTH-A | 90% | License and Development Agreement between Dyadic International (USA), Inc. and Proliant Biologicals, LLC d/b/a Proliant Health and Bio |
| RUBIC | RUBIC | 90% | RUBIC License Agreement dated April 6, 2023 |
| VTT-TECHNICAL-RESEARCH-CENTRE-OF-FINLAND-LTD | VTT-TECHNICAL-RESEARCH-CENTRE-OF-FINLAND-LTD | 90% | License Agreement with VTT Technical Research Centre of Finland Ltd dated July 17, 2017 |
| PAHC | Phibro Animal Health Corporation | 72% | Reciprocal relationship from PAHC graph: Reciprocal relationship from DYAI graph: Reciprocal relationship from PAHC graph: Reciprocal relationship from DYAI graph: use in non-pharmaceutical applicati… |
| PAHC | Phibro Animal Health Corporation | 72% | use in non-pharmaceutical applications, such as food, nutrition, and wellness. We believe the Company’s industrial heritage provides our partners with the ability to move from demonstration to commer… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| EUROPEAN-CUSTOMERS | EUROPEAN-CUSTOMERS | 90% | For each of the three months ended March 31, 2026 and 2025, the Company had one customer outside of the United States (i.e., European customers) that accounted for $ 234,397 or 21.1 % and $ 48,333 or… |
| JNJ | Johnson & Johnson | 72% | nce for royalties. Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Compa… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from DYAI graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from DYAI graph: Reciprocal relationship from JNJ grap… |
| PAHC | Phibro Animal Health Corporation | 72% | in, fibroblast growth factor (FGF), DNase I, RNase inhibitors, reagents, and enzymes for diagnostics, cell culture, and biopharmaceutical manufacturing. 7 Dyadic is engaged in multiple funded collabo… |
| PAHC | Phibro Animal Health Corporation | 72% | Reciprocal relationship from PAHC graph: Reciprocal relationship from DYAI graph: Reciprocal relationship from PAHC graph: Reciprocal relationship from DYAI graph: Reciprocal relationship from PAHC g… |
| CRAIG-HALLUM-CAPITAL-GROUP | CRAIG-HALLUM-CAPITAL-GROUP | 62% | . For performance-based awards, the Company recognizes related stock-based compensation expenses based upon its determination of the potential likelihood of achievement of the specified performance c… |
| INVESTOR-PROTECTION-CORPORATION | INVESTOR-PROTECTION-CORPORATION | 62% | es Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company currently deals with four reputable financial in… |
| PROLIANT-BIOLOGICALS-LLC | PROLIANT-BIOLOGICALS-LLC | 62% | ive securities, including 189,682 shares of unvested restricted stock units, stock options to purchase 5,635,415 shares of common stock, and stock warrants to purchase 302,600 shares of common stock,… |
| SECURITIES-INVESTOR-PROTECTION-CORPORATION | SECURITIES-INVESTOR-PROTECTION-CORPORATION | 62% | the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company currently deals with four reputable … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| DYAI-DEBT-9195 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-12-31. |
| DYAI-DEBT | Debt stack $5.1M | 90% | Market cache reports total debt of $5.1M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| DYAI-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 37 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| PAHC | Phibro Animal Health Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| JNJ | Johnson & Johnson | 100.00 | 1 | ['customer'] |
| CVRX | CVRx, Inc. | 50.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 | |
| AORT | Artivion, Inc. | 50.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 50.00 | 2 | |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 50.00 | 2 | |
| EVFM | Evofem Biosciences, Inc. | 50.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 50.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 50.00 | 2 | |
| AVTX | Avalo Therapeutics, Inc. | 50.00 | 2 | |
| CSTE | Caesarstone Ltd. | 50.00 | 2 | |
| SNNUF | Smith & Nephew plc | 50.00 | 2 | |
| ALC | Alcon Inc. | 50.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 50.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 50.00 | 2 | |
| CLGN | CollPlant Biotechnologies Ltd. | 50.00 | 2 | |
| BLCO | Bausch + Lomb Corporation | 50.00 | 2 | |
| AMIX | Autonomix Medical, Inc. | 50.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 50.00 | 2 |